Bookmark
Forward
QuickView for cefotaxime (compound)
PubChem
| Name: | Cefotaxime |
|---|---|
| PubChem Compound ID: | 10695961 |
| Description: | Semisynthetic broad-spectrum cephalosporin. |
| Molecular formula: | C16H16N5NaO7S2 |
| Molecular weight: | 477.45 g/mol |
DrugBank
Identification
| Name: | Cefotaxime |
|---|---|
| Name (isomeric): | DB00493 |
| Drug Type: | small molecule |
| Description: | Semisynthetic broad-spectrum cephalosporin. |
| Synonyms: |
Cefotaxime sodium; Cephotaxime
|
| Brand: | Claforan |
| Category: | Cephalosporins, Anti-Bacterial Agents |
| CAS number: | 63527-52-6 |
Pharmacology
| Indication: | Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery. |
|---|---|
| Pharmacology: |
Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to ...
show more » |
| Mechanism of Action: | The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III. |
| Absorption: | Rapidly absorbed following intramuscular injection. |
| Biotransformation: | Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity. |
| Route of elimination: | Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. |
| Half Life: | Approximately 1 hour. |
| Toxicity: | Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg. |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Drug interaction: |
|
|---|
Targets
Transporters
